Valion Bio

CIK 0001787740 · VBIO Nasdaq

SIC
2834 · Pharmaceutical Preparations
Type
Operating
Status
Public
Filer
Emerging growth company
Incorporated
Delaware
FY End
Dec 31

Business Summary

Tivic Health Systems, Inc. (Nasdaq: TIVC) is a late-stage biopharmaceutical company headquartered in San Antonio, Texas that underwent a fundamental strategic transformation during fiscal year 2025. The company pivoted from a diversified bioelectronic medical device company into a focused biopharmaceutical company built around its TLR5 agonist franchise. In February 2025, Tivic acquired worldwide exclusive license rights to Entolimod — a recombinant TLR5 agonist with 15+ years of development history, over 40 animal and human trials, and $140 million of prior investment including $35.6 million from U.S. government agencies (DoD/DTRA, NASA, NIH). The company exited its ClearUP consumer sinus device business in December 2025 and suspended its cervical vagus nerve stimulation platform to concentrate all resources on the TLR5 program. In December 2025, Tivic established Velocity Bioworks, Inc. (VBI) — a wholly owned CDMO subsidiary — through acquisition of manufacturing assets from Scorpius Holdings, Inc., supported by a...

Get a free account in seconds to read the full business overview. Create free account

AI-generated summary of Item 1 (Business) from the 10-K filed Mar 30, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.

Across SEC filings

Insider trades · Form 4

+$28.4K net open-market insider transactions, last 12 months 2 filings with purchases ($28.4K), 0 filings with sales ($0)

Latest filings

Federal lobbying · LD-2

$20.0K reported spend, four quarters through Q3 2026

Annual results · 10-K

Fiscal 2025
Net loss
-$8.9M

As reported in the fiscal 2025 annual report.

5%+ holders · 13D/G

2 filers
Schedule 13D and 13G filers reporting a stake of 5% or more
Filer % of class Filed
3i LP 13G VBIO 9.9% 2026-11-12
3i LP 13D VBIO 9.9% 2026-08-20
Murchinson Ltd 13G VBIO 10.0% 2026-07-17

Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.

Securities

Securities issued by this company
CUSIP Security Type
888705209 TIVC TIVIC HEALTH SYSTEMS INC Common stock
888705308 VBIO TIVIC HEALTH SYSTEMS INC Common stock

Latest SEC filings

All filings →
Latest SEC filings by Valion Bio
Form Description Filed
8-K Current Report 2026-11-16
NT 10-Q 10-Q EXTENSION FOR SEP 2026 2026-11-16
SCHEDULE 13G/A SCHEDULE 13G/A 2026-11-12
8-K CURRENT REPORT 2026-11-09
8-K Current Report 2026-11-05
8-K Current Report 2026-11-02
8-K Current Report 2026-10-29
8-K Current Report 2026-10-27
8-K Current Report 2026-10-26
8-K Current Report 2026-10-22
Loading ownership data...
Loading insider trading data...
Loading financials...

Quality is a Plus feature

See why the score is what it is — the score history and the full test-by-test breakdown behind the composite.

Valuation is a Premium feature

What this company is worth versus its price — fair value at today's bond rate, margin of safety, and the Graham Number against the institutional consensus price.

Loading SEC filings...
Loading sponsor profile...